IMMUNOHISTOCHEMISTRY, CD 117

The Immunohistochemistry (IHC) – CD117 test is a specialized diagnostic test used to detect CD117 (c-KIT) protein expression in tissue samples. CD117 is a transmembrane receptor protein involved in cell growth, development, and survival. It plays a key role in identifying certain tumors and is widely used in pathology for tumor classification and diagnosis.

This test is especially important in diagnosing Gastrointestinal Stromal Tumors (GISTs), where CD117 positivity is a major diagnostic feature. Most GISTs strongly express CD117, making this marker highly valuable for confirming diagnosis and guiding targeted treatment.

The CD117 test is also useful in diagnosing:

• Gastrointestinal stromal tumors (GISTs)
• Mast cell tumors
• Acute myeloid leukemia (AML)
• Certain melanomas
• Germ cell tumors
• Selected soft tissue and hematologic malignancies

The presence of CD117 helps pathologists identify tumor origin and classify tumors accurately. In GIST patients, CD117 positivity may also support the use of targeted therapies such as tyrosine kinase inhibitors, improving treatment outcomes.

The CD117 IHC test is commonly performed with other markers such as DOG1, CD34, Ki-67, S100, and SMA for comprehensive tissue characterization.

Benefits of the Test

The CD117 test offers several important clinical benefits:

• Detects c-KIT protein expression accurately
• Helps diagnose gastrointestinal stromal tumors
• Supports tumor classification
• Assists in identifying targeted therapy eligibility
• Improves diagnostic precision
• Helps guide treatment planning

This test is essential for accurate tumor diagnosis and personalized care.

Why Doctors Recommend This Test

Doctors recommend the CD117 test when c-KIT-positive tumors are suspected.

It is commonly advised for:

• Suspected GIST diagnosis
• Soft tissue tumor classification
• Leukemia tissue analysis
• Germ cell tumor evaluation
• Advanced pathology confirmation cases

The results help oncologists and pathologists make accurate diagnostic and therapeutic decisions.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected tissue biopsy or surgical specimens.

Normal Reporting Time

The usual turnaround time for the CD117 IHC test is 2 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with suspected GIST
• Individuals requiring tumor classification
• Patients with abnormal tissue growths
• Cases needing c-KIT expression analysis
• Oncology patients requiring targeted treatment planning

The IHC CD117 test is an important diagnostic tool in modern pathology. It supports accurate tumor classification, identifies targeted therapy opportunities, and improves patient treatment outcomes.